transcription factor 7 like 2Genealiases: TCF-4 · TCF4
Q-omics provides the consensus-scored TCF7L2 profile across patient tissues and cancer cell-line models. TCF7L2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TCF7L2 is differentially expressed in 15, with the highest sampling consensus in UCEC. Additionally, TCF7L2 RNA expression shows 20,996 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, UCEC, and ACC as cancer lineages where TCF7L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCF7L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCF7L2 survival associations across molecular data types. TCF7L2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCF7L2 RNA expression–survival associations across cancer types. High TCF7L2 expression shows unfavorable associations in ACC, but favorable associations in KIRC, UCS, BLCA, LGG and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TCF7L2 RNA expression.
This table summarizes TCF7L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCF7L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCF7L2 shows lower tumor expression in UCEC, THCA, BRCA, KICH and COAD and higher tumor expression in STAD. The UCEC box plot shows higher TCF7L2 RNA expression in normal versus tumor tissue (log2 FC = −1.495, t-test p < 0.001).
This table shows molecular features associated with TCF7L2 in patient tissues and cancer cell lines. In patient samples, TCF7L2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCF7L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
